OKYO Pharma
OKYO
1 hedge funds and large institutions have $13.7K invested in OKYO Pharma in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
59% less capital invested
Capital invested by funds: $33.3K → $13.7K (-$19.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$33.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HSBC Holdings
London,
United Kingdom
| $13.7K | +$17K | +11,933 | New |
|
|
2
Goldman Sachs
New York
| – | -$33.3K | -19,807 | Closed |
|
OKYO Hedge Fund Activity: Q2 2023 in Review
1 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2023, worth a combined $13.7K — down 59% from $33.3K a quarter earlier.
Fund positioning in OKYO was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was HSBC Holdings, opening a new position worth an estimated $17K. The largest seller was Goldman Sachs, exiting entirely with an estimated $33.3K sold.
- 1 institutional investor held OKYO Pharma (OKYO) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $13.7K of OKYO Pharma stock for Q2 2023, down 59% quarter-over-quarter.
- 1 fund opened new OKYO Pharma positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest OKYO Pharma buyer in Q2 2023 was HSBC Holdings, an estimated $17K added.
- The largest OKYO Pharma seller in Q2 2023 was Goldman Sachs, an estimated $33.3K sold.
Based on aggregated 13F filings for Q2 2023.